A copper-based drug has demonstrated a striking ability to clear the toxic protein buildup associated with Alzheimer's disease while simultaneously restoring memory function, according to research from Monash University published in ACS Chemical Neuroscience.
The compound, Cu(ATSM), works by repairing a critical waste-removal system in the brain that breaks down in Alzheimer's patients. In laboratory studies, it increased the brain's ability to eliminate harmful amyloid-beta proteins by 42 percent over 56 days while improving spatial learning by nearly 44 percent.
The breakthrough centers on how the brain's blood-brain barrier normally functions. This protective membrane controls what enters and exits the brain, relying on specialized transport proteins called P-glycoprotein pumps to move toxic waste out into the bloodstream. In Alzheimer's disease, these pumps malfunction, allowing amyloid-beta and other harmful proteins to accumulate and damage brain cells.
"This is the first study to show that Cu(ATSM) can increase the abundance of P-gp clearance pumps in an Alzheimer's model, by 24.1 percent," said Dr. Jae Pyun, lead author of the research at Monash Institute of Pharmaceutical Sciences. "By improving the pumps, the brain can finally clear out the trapped waste."
What makes this discovery particularly promising is the drug's existing track record. Cu(ATSM) has already advanced to clinical testing for other neurodegenerative conditions such as Parkinson's disease and ALS, having passed safety evaluations.
"Because reducing amyloid burden is clinically proven to improve functional outcomes, these preclinical results strongly support the rationale for testing this drug in early symptomatic Alzheimer's disease," said Professor Joseph Nicolazzo, director of the Centre for Drug Candidate Optimisation at MIPS.
Researchers suspect the drug may offer additional benefits beyond restoring pump function. They believe Cu(ATSM) could enhance the activity of microglia, the brain's immune cells responsible for consuming and breaking down amyloid plaques. However, the team is still investigating the exact mechanisms by which proteins exit the brain after the blood-brain barrier repair occurs.
The findings arrive as dementia becomes an increasingly urgent health crisis. In Australia, dementia recently surpassed coronary heart disease as the nation's leading cause of death. With aging populations worldwide and mortality from dementia continuing to climb, the search for treatments that can slow cognitive decline has become a critical priority.
The research team plans to pursue further investigation of biometal-based therapies like Cu(ATSM) as potential treatments for the blood vessel dysfunction and memory loss that define Alzheimer's disease.
Author Jessica Williams: "A drug that's already been tested in humans, that reduces amyloid by 42 percent and restores memory in lab models, should move into clinical trials fast,this has real momentum behind it."
Comments